Intravesical Gemcitabine
Preclinical
Intravesical Gemcitabine is one of 17 therapeutic programs targeting Non Muscle Invasive Bladder Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
17 competitors in Non Muscle Invasive Bladder Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Disitamab Vedotin
PfizerPhase 2
Bacillus Calmette-Guerin
AstraZenecaPhase 3
Cretostimogene Grenadenorepvec
CCG Oncology, Inc.
Phase 3
Nadofaragene Firadenovec
FerringPhase 3
Trodelvy
GileadPreclinical
Gemcitabin
GGerman Cancer Research Center
Phase 2
Theracys® BCG
FFudan University
Phase 2
TARA-002
PProtara Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Intravesical Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]